Who
Anne Marie Cook
Chief Legal Off. & Corp. Sec.
Company insider
Files Form 4 as: Chief Legal Off. & Corp. Sec., Phathom Pharmaceuticals; SVP, GC & Secretary, Sage Therapeutics; SVP, General Counsel, Aegerion Pharmaceuticals; General Counsel, SVP, Viacell.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.5M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 7 Mar 2007
- Last trade
- 10 Feb 2026
- Last filed
- 12 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,461 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K1,535 at $12.82 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,461 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $20K1,535 at $12.82 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,345 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,878 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,878 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,345 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,370 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $118K7,703 at $15.36 | filing |
| 23 Jun 2025filed 24 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | Sage Therapeutics | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | Sage Therapeutics | SEC FORM 4 Code F | $40K4,503 at $8.96 | filing |
| 13 Feb 2024filed 15 Feb 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | Sage Therapeutics | SEC FORM 4 Code A | —11,250 at $0.00 | filing |
| 28 Nov 2023filed 30 Nov 2023 | Sage Therapeutics | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 28 Nov 2023filed 30 Nov 2023 | Sage Therapeutics | SEC FORM 4 Code F | $23K1,174 at $19.27 | filing |
| 13 Feb 2023filed 15 Feb 2023 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 3 Feb 2023filed 7 Feb 2023 | Sage Therapeutics | SEC FORM 4 Code A | —2,850 at $0.00 | filing |
| 3 Feb 2023filed 7 Feb 2023 | Sage Therapeutics | SEC FORM 4 Code F | $43K980 at $44.16 | filing |
News
No headline names them, or the companies they trade most, lately.